Literature DB >> 2931063

Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy.

J G Cunha-Vaz, C C Mota, E C Leite, J R Abreu, M A Ruas.   

Abstract

To study the effect of sulindac on the alteration of the blood-retinal barrier, 24 insulin-dependent diabetic patients with minimal or no retinopathy were randomly assigned to receive either oral sulindac (200 mg twice daily) or a placebo for a period of six months. All patients underwent fundus photography, fluorescein angiography, and vitreous fluorophotometry before treatment and after 1, 3, and 6 months of treatment. Vitreous fluorophotometry data showed that there were fewer alterations of the blood-retinal barrier in the sulindac group compared with the placebo group during the six-month study period.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2931063     DOI： 10.1001/archopht.1985.01050090059032

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


  11 in total

1.  Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy.

Authors:  E B Leite; M C Mota; J R de Abreu; J G Cunha-Vaz
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

2.  Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Authors:  H J Van Schaik; B Heintz; M Larsen; E Leite; V Rosas; R Schalnus; J A Van Best
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

3.  Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics.

Authors:  S A Vinores; C Gadegbeku; P A Campochiaro; W R Green
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

Review 4.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  Quantification of macular ischaemia in sickle cell retinopathy.

Authors:  C M Lee; H C Charles; R T Smith; N S Peachey; J G Cunha-Vaz; M F Goldberg
Journal:  Br J Ophthalmol       Date:  1987-07       Impact factor: 4.638

6.  Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium.

Authors:  S A Vinores; E Van Niel; J L Swerdloff; P A Campochiaro
Journal:  Histochem J       Date:  1993-09

7.  The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.

Authors:  A Tromp; J M Hooymans; B C Barendsen; J J van Doormaal
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

8.  Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.

Authors:  J M van Gerven; J P Boot; H H Lemkes; J A van Best
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

9.  Effect of bendazac lysine on lens and retina in diabetics.

Authors:  J M Benitez del Castillo; I Jimenez-Alfaro; P Ortega; A Castillo; D Diaz; N Toledano; J Garcia-Sanchez
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

10.  Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy.

Authors:  H H Parving; M Larsen; E Hommel; H Lund-Andersen
Journal:  Diabetologia       Date:  1989-07       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.